Maria Nachury

6.9k total citations · 1 hit paper
83 papers, 2.1k citations indexed

About

Maria Nachury is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Maria Nachury has authored 83 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Genetics, 52 papers in Epidemiology and 35 papers in Surgery. Recurrent topics in Maria Nachury's work include Inflammatory Bowel Disease (71 papers), Microscopic Colitis (46 papers) and Autoimmune and Inflammatory Disorders (10 papers). Maria Nachury is often cited by papers focused on Inflammatory Bowel Disease (71 papers), Microscopic Colitis (46 papers) and Autoimmune and Inflammatory Disorders (10 papers). Maria Nachury collaborates with scholars based in France, United States and Belgium. Maria Nachury's co-authors include Marc Ferrante, Julián Panés, Jean‐Frédéric Colombel, Silvio Danese, Fernando de la Portilla, Lili Kazemi-Shirazi, Damián García‐Olmo, Eran Goldin, Jean Charles Grimaud and Anne Leselbaum and has published in prestigious journals such as The Lancet, Gastroenterology and Gut.

In The Last Decade

Maria Nachury

75 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

2016 738 citations Julián Panés, Damián García‐Olmo et al. profile →

Peers

Countries citing papers authored by Maria Nachury

Since Specialization

Citations

This map shows the geographic impact of Maria Nachury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Nachury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Nachury more than expected).

Fields of papers citing papers by Maria Nachury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Nachury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Nachury. The network helps show where Maria Nachury may publish in the future.

Co-authorship network of co-authors of Maria Nachury

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Nachury. A scholar is included among the top collaborators of Maria Nachury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Nachury. Maria Nachury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases 2025 ·The American Journal of Gastroenterology ·(unknown), Zhigang Wang, Mathurin Fuméry, Maria Nachury, (unknown), Anthony Buisson, Erwin Dreesen	0
2	Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease 2025 ·Therapeutic Advances in Gastroenterology ·(unknown), Mathurin Fuméry, Maria Nachury, Clara Yzet, Dilek Çoban, Anthony Buisson	0
3	DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort 2024 ·Journal of Crohn s and Colitis ·Cathérine Reenaers, (unknown), Maria Nachury, David Laharie, Yoram Bouhnik, Mathurin Fuméry, J.M. Gornet, Aurélien Amiot, Romain Altwegg, Martine De Vos, Philippe Marteau, Arnaud Bourreille, Stéphane Nancey, Stéphanie Viennot, Édouard Louis, Magali Svrcek	1
4	Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort 2024 ·Journal of Crohn s and Colitis ·Cathérine Reenaers, (unknown), Maria Nachury, David Laharie, (unknown), Mathurin Fuméry, (unknown), Aurélien Amiot, Romain Altwegg, Martine De Vos, Philippe Marteau, Arnaud Bourreille, Stéphane Nancey, S Viennot, Édouard Louis, Magali Svrcek	1
5	Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study 2024 ·Digestive and Liver Disease ·(unknown), (unknown), Pauline Wils, Nadia Arab, (unknown), Aurélien Amiot, (unknown), Lucine Vuitton, Mathurin Fuméry, Romain Altwegg, Maria Nachury, Xavier Hébuterne, Clara Yzet, Dilek Çoban, (unknown), (unknown), Bruno Pereira, Anthony Buisson	2
6	Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study 2023 ·Alimentary Pharmacology & Therapeutics ·Anthony Buisson, Maria Nachury, (unknown), Clara Yzet, Pauline Wils, (unknown), Dilek Çoban, Bruno Pereira, Mathurin Fuméry	10
7	Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study 2023 ·Clinical Gastroenterology and Hepatology ·Anthony Buisson, Maria Nachury, Bruno Pereira, Mathurin Fuméry	3
8	Role of adherent and invasive Escherichia coli in Crohn’s disease: lessons from the postoperative recurrence model 2022 ·Gut ·Anthony Buisson, Harry Sokol, Nassim Hammoudi, Stéphane Nancey, Xavier Tréton, Maria Nachury, Mathurin Fuméry, Xavier Hébuterne, (unknown), Jean‐Pierre Hugot, Gilles Boschetti, Carmen Stefănescu, Pauline Wils, Philippe Seksik, Lionel Le Bourhis, Madeleine Bezault, Pierre Sauvanet, Bruno Pereira, Matthieu Allez, Nicolas Barnich	33
9	Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent 2022 ·Alimentary Pharmacology & Therapeutics ·Anthony Buisson, Maria Nachury, (unknown), Romain Altwegg, Xavier Tréton, Mathurin Fuméry, Mélanie Serrero, (unknown), Ludovic Caillo, Bruno Pereira, Aurélien Amiot, Guillaume Bouguen	15
10	Comparison of the Risk of Crohn’s Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis 2022 ·Journal of Crohn s and Colitis ·Pauline Rivière, Joel Pekow, Nassim Hammoudi, Pauline Wils, Peter De Cruz, (unknown), Míriam Mañosa, Jacob E. Ollech, Matthieu Allez, Maria Nachury, Michael A. Kamm, (unknown), Marc Ferrante, Anthony Buisson, Siddarth Singh, David Laharie, Momar Diouf, Mathurin Fuméry	17
11	Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study 2022 ·Clinical Gastroenterology and Hepatology ·Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, (unknown), (unknown), (unknown), (unknown), (unknown), Mathurin Fuméry	53
12	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort 2021 ·Alimentary Pharmacology & Therapeutics ·Mathieu Uzzan, (unknown), David Laharie, Carmen Stefănescu, (unknown), Franck Carbonnel, Mélanie Serrero, Stéphanie Viennot, Maria Nachury, Aurélien Amiot, Romain Altwegg, Laurence Picon, Stéphane Nahon, Lucine Vuitton, (unknown), Julien Kirchgesner, Laurent Peyrin‐Biroulet, Yoram Bouhnik, (unknown)	36
13	Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients 2020 ·Alimentary Pharmacology & Therapeutics ·(unknown), Anne Bourrier, Maria Nachury, Stéphane Nancey, Yoram Bouhnik, Mélanie Serrero, Laura Armengol‐Debeir, Anthony Buisson, My‐Linh Tran‐Minh, Camille Zallot, Mathurin Fuméry, Guillaume Bouguen, Véred Abitbol, Stéphanie Viennot, Elise Chanteloup, Sylvie Rajca, Nina Dib, Anne-Laure Parmentier, Laurent Peyrin‐Biroulet, Lucine Vuitton, (unknown)	46
14	Motivation to pursue anti-TNFα treatment in patients with Crohn's disease – the SPACE motivation study 2020 ·Digestive and Liver Disease ·Ferdinando D’Amico, Laurent Peyrin‐Biroulet, Luc Vandromme, Yoram Bouhnik, Patrick Fauré, Stéphane Nahon, Hervé Hagège, Xavier Hébuterne, (unknown), Maria Nachury	1
15	Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis 2018 ·Clinical Gastroenterology and Hepatology ·(unknown), Carmen Stefănescu, Franck Carbonnel, Laurent Peyrin‐Biroulet, Xavier Roblin, (unknown), Maria Nachury, Stéphane Nancey, Jérôme Filippi, Romain Altwegg, Hédia Brixi, (unknown), (unknown), Sarah Shili, David Laharie	51
16	Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab 2016 ·Digestive and Liver Disease ·(unknown), Maria Nachury, Romain Gérard, Julien Branche, V. Maunoury, Médina Boualit, Pauline Wils, Pierre Desreumaux, Benjamin Pariente	13
17	A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn's disease 2016 ·Julián Panés, Damián García‐Olmo, Gert Van Assche, (unknown), Walter Reinisch, (unknown), Maria Nachury, Marc Ferrante, Lili Kazemi-Shirazi, (unknown), Fernando de la Portilla, Ehud Goldin, Anne Leselbaum, Mary Carmen Díez, Silvio Danese	3
18	Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn’s Disease Patients Classified i2 on the Rutgeerts Score 2016 ·Digestive Diseases and Sciences ·(unknown), (unknown), Maria Nachury, Philippe Zerbib, Romain Gérard, Julien Branche, V. Maunoury, Pauline Wils, Arnaud Boruchowicz, Médina Boualit, J E Laberenne, (unknown), Pierre Desreumaux, Guillaume Pineton de Chambrun, Benjamin Pariente	29
19	Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn’s Disease: A Prospective Cohort-Study in High-Risk Patients 2016 ·Journal of Crohn s and Colitis ·M. Simon, Jacques Cosnes, J.M. Gornet, Philippe Seksik, Carmen Stefănescu, Antoine Blain, Benjamin Pariente, Stéphane Nancey, Lucine Vuitton, Maria Nachury, Geert D’Haens, Jérôme Filippi, Sylvie Chevret, David Laharie, (unknown)	19
20	P475. What is our success on complex perianal fistulae healing under optimal medical treatment ending up with ileostomy? 2015 ·Journal of Crohn s and Colitis ·Michael P. Collins, Hélène Sarter, Corinne Gower‐Rousseau, (unknown), Maria Nachury, (unknown), Antoine Cortot, Philippe Zerbib, Jean–Frédéric Colombel, Laurent Peyrin‐Biroulet, Pierre Desreumaux, Guillaume Pineton de Chambrun	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact